Saudi Arabia Women’s Health Market Size & Outlook
Saudi Arabia women’s health market, 2018-2030 (US$M)
Related Markets
Saudi Arabia women’s health market highlights
- The Saudi Arabia women’s health market generated a revenue of USD 270.9 million in 2023 and is expected to reach USD 414.6 million by 2030.
- The Saudi Arabia market is expected to grow at a CAGR of 6.3% from 2024 to 2030.
- In terms of segment, contraceptives was the largest revenue generating application in 2023.
- Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
Women’s health market data book summary
| Market revenue in 2023 | USD 270.9 million |
| Market revenue in 2030 | USD 414.6 million |
| Growth rate | 6.3% (CAGR from 2023 to 2030) |
| Largest segment | Contraceptives |
| Fastest growing segment | Endometriosis & Uterine Fibroids |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, Saudi Arabia accounted for 0.6% of the global women’s health market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia women’s health market is projected to lead the regional market in terms of revenue in 2030.
- South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 323.6 million by 2030.
Contraceptives was the largest segment with a revenue share of 36.66% in 2023. Horizon Databook has segmented the Saudi Arabia women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.
According to the International Osteoporosis Foundation, around 1.3 million individuals aged 55 or more and around 8,768 individuals suffer femoral fractures annually for USD 150.60 million. Infertility rates in Saudi Arabia and GCC countries are growing and are over double the global average.
Moreover, according to an article published by Al Arabiya Network in August 2022, the global infertility rate is around 15%, while the GCC infertility rate is around 35%–40%. Moreover, vitamin D deficiency is more prominent in women of varying ages in Saudi Arabia.
The region has a high prevalence of vitamin D deficiency, accounting for nearly 41.2% of the total women population in the country, and it is higher in postmenopausal women. Among them, premenopausal women aged from 20 to 40 had the highest prevalence of vitamin D deficiency (80.5%), and about 86.2% of postmenopausal women aged 60 & above were vitamin D deficient.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Women’s Health Market Scope
Women’s Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Saudi Arabia women’s health market size, by application, 2018-2030 (US$M)
Saudi Arabia Women’s Health Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
